Craft

Tissue Regenix Group

Stock Price

£0.5

2024-10-29

Market Capitalization

£39.6 M

2024-10-29

Revenue

$31.8 M

FY, 2024

Tissue Regenix Group Summary

Company Summary

Overview
Tissue Regenix was established in May 2006 and is dedicated to the development of clinical solutions to address the chronic shortfalls in donor tissue availability in areas such as Vascular and Orthopaedic medicine. There is a well established clinical need for more donor tissue for many surgical procedures. Tissue Regenix will develop and commercialise acellular tissue repair products to meet this need, to ultimately benefit patients.
Type
Public
Status
Active
Founded
2006
HQ
Swillington, GB | view all locations
Website
http://www.tissueregenix.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Steve Couldwell

    Steve Couldwell, CEO

    • Jesus Hernandez

      Jesus Hernandez, CEO CellRight Technologies

      • Mike Izon, Technical Director

        • Andrea Rausch

          Andrea Rausch, Commercial Director – Cardiac

          LocationsView all

          3 locations detected

          • Swillington HQ

            United Kingdom

            Astley Way

          • Universal City, TX

            United States

            1808 Universal City Blvd

          • Garforth, England

            United Kingdom

            Phoenix Court, Lotherton Way

          Tissue Regenix Group Financials

          Summary Financials

          Revenue (H1, 2025)
          $13.8M
          Gross profit (H1, 2025)
          $6.3M
          Net income (H1, 2025)
          ($957.0K)
          Cash (H1, 2025)
          $1.1M
          EBIT (H1, 2025)
          ($378.0K)
          Enterprise value
          $49.5M

          Footer menu